Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy

Executive Summary

Parent Project Muscular Dystrophy’s proposed guidance gives detail on biomarkers and clinical trial designs for the beleaguered field, but most importantly addresses benefit-risk assessment – which is FDA’s underlying ambition for the patient-focused drug development initiative.

You may also be interested in...



FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings

After conducting 24 disease-focused meetings in five years, FDA moving to next phase of patient interaction under new user fee cycle.

US FDA Planning Another Patient Group To Boost Involvement

Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.

US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'

FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel